Totonchy Study Guide - work in progress

0.0(0)
studied byStudied by 0 people
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/45

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

46 Terms

1
New cards

What does the suffix "-ximab" indicate about a monoclonal antibody?

It is chimeric

2
New cards

What does the suffix "-zumab" indicate about a monoclonal antibody?

It is humanized

3
New cards

What does the suffix "-omab" indicate about a monoclonal antibody?

It is mouse-derived

4
New cards

What does the suffix "-umab" indicate about a monoclonal antibody?

It is fully human

5
New cards

Rituximab is a monoclonal antibody. What type is it based on its name?

Chimeric

6
New cards

Trastuzumab is a monoclonal antibody. What type is it based on its name?

Humanized

7
New cards

Muromonab is a monoclonal antibody. What type is it based on its name?

Mouse-derived

8
New cards

Adalimumab is a monoclonal antibody. What type is it based on its name?

Fully human

9
New cards

Bevacizumab is a monoclonal antibody. What type is it based on its name?

Humanized

10
New cards

Cetuximab is a monoclonal antibody. What type is it based on its name?

Chimeric

11
New cards

Which applications of mAb therapeutics require the Fc region?

TNF alpha therapeutics

  • Infliximab

  • Adalimumab

  • Etanercept

12
New cards

What is one stability advantage of nanobodies compared to mammalian immunoglobulins?

Nanobodies are more resistant to pH changes and denaturation

13
New cards

Nanobodies are easier to manufacture because they are composed of only ______

one protein

14
New cards

True or False: Nanobodies have a longer half-life than mammalian immunoglobulins

False. Nanobodies have a shorter half-life compared to mammalian immunoglobulins

15
New cards

What is one drawback of the small size of nanobodies as therapeutics?

Reduced bioavailability

16
New cards

True or False: Nanobodies do not require an identified target for their use.

False. Nanobodies require an identified target for therapeutic applications

17
New cards

The Fc region of a monoclonal antibody is required for applications such as ______ therapeutics

TNF alpha

18
New cards

What does an antibody with an Fc region look like?

See image

<p>See image</p>
19
New cards

Name three monoclonal antibodies used as TNF alpha therapeutics.

Infliximab, Adalimumab, and Etanercept

20
New cards

Which applications require two antigen binding sites and what are these antibodies

called?

Cross linking

  • Emicizumab

  • Bispecific antibody

21
New cards

Which applications require a small structure like a fragment?

Single Chain mAb application

  • Nanobody

22
New cards

What terms are used for therapeutics that use the patient’s own cells?

Autogenic/autologous

23
New cards

What terms are used for therapeutics that use other people’s cells?

Allogenic/heterologous

24
New cards

What is a major limiting factor for the development of CAR T cell therapeutics?

The need for a defined protein target

25
New cards

Why must CAR T cell targets be highly specific?

To avoid off-target toxicities

26
New cards

True or False: CAR T cell therapy can target any protein regardless of its specificity

False. CAR T cell therapy requires a specific target to minimize off-target toxicities

27
New cards

What is an example of "on-target but off-tumor" toxicity in CAR T cell therapy?

Targeting CD19 in tumor cells but also destroying normal B cells that express CD19, leading to immunosuppression

28
New cards

What systemic toxicity is commonly associated with CAR T cell therapy?

Cytokine storm caused by the activation and proliferation of CAR T cells

29
New cards

The systemic cytokine toxicities in CAR T cell therapy result from the activation of the ______

immune system

30
New cards

What is the goal of gene silencing in gene therapy?

To reduce or prevent the expression of a protein from a mutated gene

31
New cards

True or False: Gene silencing is a permanent solution to fix defective genes

False. Gene silencing is temporary and requires continuous therapy

32
New cards

What is the advantage of gene silencing in gene therapy?

It eliminates overactive defective genes without causing permanent alterations

33
New cards

What is the purpose of genome editing in gene therapy?

To fix the mutated gene directly

34
New cards

True or False: Genome editing in gene therapy has no risks of unintended effects.

False. Genome editing can cause off-target mutations

35
New cards

What is ectopic expression in gene therapy?

Adding a good copy of the mutated gene to restore function

36
New cards

Ectopic expression often uses ______, which can be dangerous

viral vectors

37
New cards

What is a disadvantage of ectopic expression in gene therapy?

It may not result in long-term effects for all applications

38
New cards

What are the three approaches for gene therapy?

  • Gene silencing

  • Genome editing

  • Ectopic expression

39
New cards

Which type of virus used in gene therapy is mostly episomal but can also integrate?

Adeno-associated virus (AAV)

40
New cards

True or False: Adeno-associated virus (AAV) is always an integrating vector.

False. AAV is mostly episomal but can sometimes integrate

41
New cards

What type of vector is lentivirus in gene therapy?

Integrating vector

42
New cards

The ______ platform is an episomal vector used in gene therapy

HSV1 STAR-D

43
New cards

True or False: Lentivirus is an episomal vector.

False. Lentivirus is an integrating vector

44
New cards

What is the only FDA approved oncolytic therapeutic (only specific therapeutic

mentioned on the exam)

Imlygic

45
New cards

What are the ethical and practical reasons behind placebo choice for vaccine clinical trials.

Should mimic the same side effects but still not put the patient at risk. Patients

should still have equal protection from the disease.

46
New cards

Which vaccine types require specific target antigens to be selected during development?

  • Subunit

  • Recombinant

  • mRNA

  • Viral vector

  • Conjugate